drugset
drugset / Trial / NCT04727541

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

NCT04727541 ↗

Phase 2 Terminated 3 enrolled AIO-Studien-gGmbH Merck Serono GmbH, Germany · collab
NaSingle-groupOpen-labelTreatment

Summary

The NEOBIL study aims to investigate the feasibility, safety and efficacy of neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer.

Timeline

Start
2021-07-08
Primary completion
2021-10-04
Completion
2022-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bintrafusp alfa Protein / enzyme biologic 1200 mg Intravenous

Indications

cholangiocarcinoma